Clover Health Investments

CLOV

Market cap $1.59B

Overview Fund Activity

3.10 USD

+0.03

0.98%

At close Updated Sep 18, 2:57 PM EDT

1 day

0.98%

5 days

-1.27%

1 month

18.77%

3 months

4.38%

6 months

-18.64%

Year to date

-0.96%

1 year

3.33%

5 years

-75.32%

10 years

-69.61%

About: Clover Health Investments Corp is a healthcare technology company. It focuses on empowering Medicare physicians to proactively manage chronic diseases through its proprietary software platform, Clover Assistant. This cloud-based solution provides personalized insights to physicians, enabling early detection and management of chronic conditions. It operates in one segment: Insurance, through which it offers PPO and HMO plans to Medicare Advantage members in several states.

Employees: 570

Healthcare Healthcare Plans

0

Funds holding %

of 7,463 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

89% more repeat investments, than reductions

Existing positions increased: 68 | Existing positions reduced: 36

76% more call options, than puts

Call options by funds: $16.5M | Put options by funds: $9.33M

9.78% more ownership

Funds ownership: 25.29% [Q1] → 35.07% (+9.78%) [Q2]

7% more capital invested

Capital invested by funds: $380M [Q1] → $408M (+$27.5M) [Q2]

4% more first-time investments, than exits

New positions opened: 51 | Existing positions closed: 49

2% less funds holding

Funds holding: 198 [Q1] → 194 (-4) [Q2]

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$3

3% downside

Avg. target

$3.55

15% upside

High target

$4.1

32% upside

2 analyst ratings

1 positive

50%

1 neutral

50%

0 negative

0%

Canaccord Genuity Richard Close	$4.1	Buy Maintained	7 Aug 2025
UBS Jonathan Yong	$3	Neutral Maintained	6 Aug 2025

See Analyst Rankings

Financial journalist opinion

Based on 6 articles about CLOV published over the past 30 days

Clover Health Celebrates the Election of Dr. Ian Duncan, Clover MA Board Member, as the 2025-2026 President-Elect and Vice-Chair of the Society of Actuaries

Dr. Duncan's appointment to this prestigious role recognizes his extraordinary contributions to the actuarial profession and healthcare innovation over three decades Dr. Duncan's appointment to this prestigious role recognizes his extraordinary contributions to the actuarial profession and healthcare innovation over three decades

Clover Health Celebrates the Election of Dr. Ian Duncan, Clover MA Board Member, as the 2025-2026 President-Elect and Vice-Chair of the Society of Actuaries

Clover Health Launches New Portal Availity® Essentials™ to Empower Providers and Improve the Patient Experience

Clover Health Continues to Invest in Streamlining Provider Workflows and Reducing Administrative Burden Through Technology and Operational Improvements Clover Health Continues to Invest in Streamlining Provider Workflows and Reducing Administrative Burden Through Technology and Operational Improvements

Clover Health Launches New Portal Availity® Essentials™ to Empower Providers and Improve the Patient Experience

Counterpart Health Launches Integrated Scribing, Supercharging Counterpart Assistant with Smarter, Seamless Scribing Built for Value-Based Care

The latest AI-powered feature in Counterpart Assistant streamlines documentation, enhances physician workflows, and raises the bar for value-based care across practice settings at no additional cost to users The latest AI-powered feature in Counterpart Assistant streamlines documentation, enhances physician workflows, and raises the bar for value-based care across practice settings at no additional cost to users

Counterpart Health Launches Integrated Scribing, Supercharging Counterpart Assistant with Smarter, Seamless Scribing Built for Value-Based Care

Clover Health CEO Andrew Toy Testifies Before Congress on the Transformative Role of AI in Healthcare, Highlights how Clover is Leading the Way

WASHINGTON, D.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (Nasdaq: CLOV) (“Clover,” “Clover Health” or the “Company”) – Clover Health CEO Andrew Toy today had the honor to deliver testimony before the U.S. House of Representatives Committee on Energy and Commerce Subcommittee on Health, positioning Clover as a national leader in AI-enabled healthcare transformation.

Clover Health CEO Andrew Toy Testifies Before Congress on the Transformative Role of AI in Healthcare, Highlights how Clover is Leading the Way

Zacks Investment Research

Here's Why You Should Add CLOV Stock to Your Portfolio Now

Clover's strong membership growth, rising revenues, and first-half EBITDA profitability highlight its tech-driven Medicare Advantage edge.

Here's Why You Should Add CLOV Stock to Your Portfolio Now

Zacks Investment Research

Bears are Losing Control Over Clover Health Investments (CLOV), Here's Why It's a 'Buy' Now

Clover Health Investments (CLOV) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.

Bears are Losing Control Over Clover Health Investments (CLOV), Here's Why It's a 'Buy' Now

Clover Health: Short-Term Pain Hides Its Long-Term Profitability Potential

While Clover Health's Q2 earnings showed continued member and revenue growth, it dropped 30% since then due to higher medical costs that impacted all MA plan providers. Clover Health still maintains industry-leading medical cost ratios despite the short-term cost headwinds, a testament to its tech-based business model. The implementation of negotiated drug prices in 2026, combined with the 5.06% MA payout increase by CMS and the 5% quality bonus, could help Clover offset the higher medical costs.

Clover Health: Short-Term Pain Hides Its Long-Term Profitability Potential

Zacks Investment Research

CLOV Q2 Earnings In Line, Stock Falls on Raised Insurance BER View

Clover Health's Q2 revenues rise 34%, but raised Insurance BER guidance and margin pressures cause shares to tumble post-earnings.

CLOV Q2 Earnings In Line, Stock Falls on Raised Insurance BER View

The Motley Fool

Clover Health (CLOV) Q2 Sales Up 34%

Clover Health (CLOV) Q2 Sales Up 34%

Clover Health (CLOV) Q2 Sales Up 34%

Clover Health Investments, Corp. (CLOV) Q2 2025 Earnings Call Transcript

Clover Health Investments, Corp. (NASDAQ:CLOV ) Q2 2025 Earnings Conference Call August 5, 2025 5:00 PM ET Company Participants Andrew Toy - Co-Founder, CEO & Director Peter J. Kuipers - Chief Financial Officer Ryan Schmidt - Corporate Participant Investor Relations Analyst - Corporate Participant Conference Call Participants John Granville Pinney - Canaccord Genuity Corp., Research Division Matthew Gregory Hewitt - Craig-Hallum Capital Group LLC, Research Division Operator Ladies and gentlemen, good afternoon, and welcome to the Clover Health Second Quarter 2025 Earnings Conference Call.

Clover Health Investments, Corp. (CLOV) Q2 2025 Earnings Call Transcript

See News Rankings

Charts implemented using Lightweight Charts™